Form 4: Adaptimmune Therapeutics Director Acquires Options to Purchase 660,000 Ordinary Shares

Kristen Hege, a director of Adaptimmune Therapeutics PLC, acquired options to purchase 660,000 ordinary shares on July 1, 2024, at an exercise price of $0.16.

Summary

• On July 1, 2024, Kristen Hege, a director of Adaptimmune Therapeutics PLC, filed a Form 4 indicating a change in beneficial ownership.
• Hege acquired options to purchase 660,000 ordinary shares of Adaptimmune Therapeutics.
• The exercise price of the options is $0.16 per share, converted from GBP0.13 based on an exchange rate of U.S.$ 1.263714 to GBP1.00.
• The options are exercisable from July 1, 2025, and expire on July 1, 2034.
• Following the transaction, Hege directly owns options to purchase 660,000 ordinary shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of a director's stock option acquisition. While insider buying can be seen as positive, option grants are part of compensation and don't necessarily indicate strong positive sentiment.

Positives

• A director's acquisition of options can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure related to insider transactions and provides insight into the actions of company directors. It is common for directors to receive stock options as part of their compensation.

Stakeholder Impact

• The acquisition of options by a director could have a minor positive impact on shareholder sentiment.

Key Dates